A practical reference on Alpha-MSH: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-07-09 and is reviewed periodically as new material appears.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic cyclic heptapeptide | Analog of alpha-MSH with an internal lactam bridge |
| Molecular weight | Approximately 1024 daltons | Free base value; salt forms differ |
| Appearance | White to off-white powder | Usually supplied as a lyophilized solid |
| Solubility | Freely soluble in water | Poorly soluble in nonpolar solvents |
| Typical storage | −20 °C, dry, protected from light | Repeated freeze-thaw cycles degrade peptides |
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
=== Career === On 22 December 1884, Thomson was appointed Cavendish Professor of Physics at the University of Cambridge. This appointment caused considerable surprise; candidates such as Osborne Reynolds and Richard Glazebrook were older and more experienced in laboratory work, whereas Thomson was known for his work as a mathematician—being recognised as an exceptional talent. Thomson was knighted in 1908 and appointed to the Order of Merit in 1912. At Oxford, he gave the 1914 Romanes Lecture titled The Atomic Theory. In 1918, he became Master of Trinity College, Cambridge, a position he held until his death on 30 August 1940. His ashes rest in Westminster Abbey, near the graves of Isaac Newton and his former student, Ernest Rutherford. Rutherford succeeded him as Cavendish Professor. Six of Thomson's research assistants and junior colleagues (Charles Glover Barkla, Niels Bohr, Max Born, William Henry Bragg, Owen Willans Richardson and Charles Thomson Rees Wilson) won the Nobel Prize in Physics, and two (Francis William Aston and Ernest Rutherford) won the Nobel Prize in Chemistry. Thomson's son, George Paget Thomson, won the 1937 Nobel Prize in Physics for proving the wave-like properties of electrons.
== External links == Nutmeg - Erowid Nutmeg Reports - Erowid Experience Vaults - Erowid Nutmeg - PsychonautWiki The Big & Dandy Nutmeg Thread - Bluelight Myristicin - Isomer Design Myristica fragrans: An Exploration of the Narcotic Spice (2008) - Ibo Nagano - The Entheogen Review - Erowid
Natural strontium is a mixture of four stable isotopes: 84Sr, 86Sr, 87Sr, and 88Sr. Of these isotopes, 88Sr is the most abundant, making up about 82.6% of all natural strontium, though the abundance varies somewhat due to the production of radiogenic 87Sr as the daughter of long-lived beta-decaying 87Rb. This is the basis of rubidium–strontium dating. Of the unstable isotopes, the primary decay mode of the isotopes lighter than 86Sr is electron capture or positron emission to isotopes of rubidium, and that of the isotopes heavier than 88Sr is electron emission to isotopes of yttrium. Of special note are 89Sr and 90Sr. The former has a half-life of 50.56 days and is used to treat bone cancer due to strontium's chemical similarity and hence ability to replace calcium. While 90Sr (half-life 28.91 years) has been used similarly, it is more an isotope of concern in fallout from nuclear weapons and nuclear accidents due to its longer life (both are produced as fission products). Its presence in bones, where all strontium accumulates, can cause bone cancer, cancer of nearby tissues, and leukemia. The 1986 Chernobyl nuclear accident contaminated about 30,000 km2 with greater than 10 kBq/m2 of 90Sr, or an estimated 5% of the reactor's total content of 90Sr.
In 2004, the Uni-President Group introduced Mister Donut in Taiwan through the newly established joint-venture Mister Donut Taiwan Corp., announcing a goal to open 100 outlets in Taiwan in three years.
Sources: en.wikipedia.org
A radioactive tracer, radiotracer, or radioactive label is a synthetic derivative of a natural compound in which one or more atoms have been replaced by a radionuclide (a radioactive atom). By virtue of its radioactive decay, it can be used to explore the mechanism of chemical reactions by tracing the path that the radioisotope follows from reactants to products. Radiolabeling or radiotracing is thus the radioactive form of isotopic labeling. In biological contexts, experiments that use radioisotope tracers are sometimes called radioisotope feeding experiments. Radioisotopes of hydrogen, carbon, phosphorus, sulfur, and iodine have been used extensively to trace the path of biochemical reactions. A radioactive tracer can also be used to track the distribution of a substance within a natural system such as a cell or tissue, or as a flow tracer to track fluid flow. Radioactive tracers are also used to determine the location of fractures created by hydraulic fracturing in natural gas production. Radioactive tracers form the basis of a variety of imaging systems, such as, PET scans, SPECT scans and technetium scans. Radiocarbon dating uses the naturally occurring carbon-14 isotope as an isotopic label. In radiopharmaceutical sciences some misuse of established scientific terms exist. Therefore an international "Working Group on Nomenclature in Radiopharmaceutical Chemistry and Related Areas" was formed in 2015 by the Society of Radiopharmaceutical Sciences (SRS).
== Membrane separation processes == Membrane separation processes have a very important role in the separation industry. Nevertheless, they were not considered technically important until the mid-1970s. Membrane separation processes differ based on separation mechanisms and size of the separated particles. The widely used membrane processes include microfiltration, ultrafiltration, nanofiltration, reverse osmosis, electrolysis, dialysis, electrodialysis, gas separation, vapor permeation, pervaporation, membrane distillation, and membrane contactors. All processes except for pervaporation involve no phase change. All processes except electrodialysis are pressure driven. Microfiltration and ultrafiltration is widely used in food and beverage processing (beer microfiltration, apple juice ultrafiltration), biotechnological applications and pharmaceutical industry (antibiotic production, protein purification), water purification and wastewater treatment, the microelectronics industry, and others. Nanofiltration and reverse osmosis membranes are mainly used for water purification purposes. Dense membranes are utilized for gas separations (removal of CO2 from natural gas, separating N2 from air, organic vapor removal from air or a nitrogen stream) and sometimes in membrane distillation. The later process helps in the separation of azeotropic compositions reducing the costs of distillation processes.
== Substrates and products of fermentation == Like many biochemical reactions, fermentation is an enzyme catalyzed reaction with the goal of either changing the initial substrate or forming a useful byproduct. When naturally occurring fermentation is carried out by microbes, the goal is usually to obtain useful metabolic products such as ATP, pyruvate, or lactic acid. The substrates used in this type of fermentation are often simple sugars (carbohydrates) that serve as a carbon source and this type of fermentation can be carried out by microbes and humans. Food as a substrate for fermentation is the most common and oldest anthropogenic use of fermentation as it was a method to preserve food. This includes cereal, dairy products, rice, honey, bread, and beers. This type of naturally occurring fermentation continues to be harnessed by humans for preservative effects, flavor profiles, and texture profiles. Advances in fermentation has led to the engineering and industrialization of specific microbes and substrates in order to obtain certain flavor and texture profiles – this is most obvious when observing beer fermentation.
Italy was a postwar operator of P-51Ds; deliveries were slowed by the Korean War, but between September 1947 and January 1951, by MDAP count, 173 examples were delivered. They were used in all the AMI fighter units: 2, 3, 4, 5, 6 and 51 Stormo (wing), plus some employed in schools and experimental units. Considered a "glamorous" fighter, P-51s were even used as personal aircraft by several Italian commanders. Some restrictions were placed on its use due to unfavorable flying characteristics. Handling had to be done with much care when fuel tanks were fully used, and several aerobatic maneuvers were forbidden. Overall, the P-51D was highly rated even compared to the other primary postwar fighter in Italian service, the Supermarine Spitfire, partly because these P-51Ds were in very good condition in contrast to all other Allied fighters supplied to Italy. Phasing out of the Mustang began in mid-1958. Japan The P-51C-11-NT Evalina, marked as "278" (former USAAF serial: 44-10816) and flown by 26th FS, 51st FG, was hit by gunfire on 16 January 1945 and belly-landed on Suchon Airfield in China, which was held by the Japanese. The Japanese repaired the aircraft, roughly applied Hinomaru roundels and flew the aircraft to the Fussa evaluation center (now Yokota Air Base) in Japan. Netherlands
Most notable was a large emphasis on partnerships and collaborations to ensure that the majority of PSI research is focused on proteins of interest to the broader research community as well as efforts to make PSI products more accessible to the research community. Grant applications for PSI:Biology were submitted by October 29, 2009. See Phase 3 section above.
Sources: en.wikipedia.org
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.
Melanotan-1, also called afamelanotide, is a shorter linear analog with a different amino acid sequence and no lactam ring. It has been evaluated in formal clinical programs, while melanotan-2 has not. The two are distinct molecules and are not interchangeable.
No. Bremelanotide is a related but distinct cyclic peptide that reached approved status for one specific clinical indication. Melanotan-2 is a separate molecule with its own sequence and properties. Shared ancestry in the melanocortin family does not make them the same substance.
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.